120 results on '"Pitt, Bertram"'
Search Results
2. ENHANCED INHIBITION OF ALDOSTERONE PRODUCTION BY PB6440, A NOVEL AND VERY HIGHLY SELECTIVE ALDOSTERONE SYNTHASE INHIBITOR.
- Author
-
Jowett, James, Pitt, Bertram, Schotzinger, Robert, and Lee, John
- Subjects
- *
ALDOSTERONE , *ALDOSTERONE antagonists - Published
- 2023
- Full Text
- View/download PDF
3. Alteration of Relation of Atherogenic Lipoprotein Cholesterol to Apolipoprotein B by Intensive Statin Therapy in Patients With Acute Coronary Syndrome (from the Limiting UNdertreatment of lipids in ACS With Rosuvastatin [LUNAR] Trial).
- Author
-
Ballantyne, Christie M., Pitt, Bertram, Loscalzo, Joseph, Cain, Valerie A., and Raichlen, Joel S.
- Subjects
- *
LIPOPROTEINS , *ACUTE coronary syndrome , *LOW density lipoproteins , *ROSUVASTATIN , *REGRESSION analysis , *ANALYSIS of triglycerides , *PATIENTS - Abstract
The low-density lipoprotein (LDL) cholesterol goal of <70 mg/dl, recommended for patients with acute coronary syndrome, typically requires intensive therapy with high-dose statins. The secondary goals of nonLhigh-density lipoprotein (non-HDL) cholesterol <100 mg/dl and apolipoprotein B (ApoB) <80 mg/dl have been recommended to reduce excess cardiovascular risk not captured by LDL cholesterol. The present post hoc analysis from the Limiting UNdertreatment of lipids in Acute coronary syndrome with Rosuvastatin (LUNAR) study examined the relation of ApoB with LDL cholesterol and non-HDL cholesterol at baseline and during treatment with intensive statin therapy. The LUNAR participants had acute coronary syndrome and received rosuvastatin 40 mg/day or 20 mg/day or atorvastatin 80 mg/day for 12 weeks. Linear regression analyses were used to compare ApoB, direct LDL cholesterol, and non-HDL cholesterol at baseline and during therapy. Of the 682 patients included in the analysis, 220 had triglycerides ≥200 mg/dl. Linear regression analysis showed that correlation of ApoB and non-HDL cholesterol was stronger than that of ApoB and LDL cholesterol and stronger with statin therapy than at baseline (R² = 0.93 for ApoB vs non-HDL cholesterol with statins). The target of ApoB of 80 mg/dl correlated with LDL cholesterol of 90 mg/dl and non-HDL cholesterol of 110 mg/dl at baseline and with LDL cholesterol of 74 mg/dl and non-HDL cholesterol of 92 mg/dl with statin therapy. For high-triglyceride patients, the corresponding on-treatment targets were LDL cholesterol of 68 mg/dl and non-HDL cholesterol of 92 mg/dl. In conclusion, non-HDL cholesterol is an adequate surrogate of ApoB during statin therapy, independent of triglyceride status. However, to match LDL cholesterol and ApoB treatment goals in the very-high-risk category, the current non-HDL cholesterol goal should be lowered by 8 to 10 mg/dl. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
4. Comparison of Lipid-Modifying Efficacy of Rosuvastatin Versus Atorvastatin in Patients With Acute Coronary Syndrome (from the LUNAR Study)
- Author
-
Pitt, Bertram, Loscalzo, Joseph, Monyak, John, Miller, Elinor, and Raichlen, Joel
- Subjects
- *
COMPARATIVE studies , *STATINS (Cardiovascular agents) , *ACUTE coronary syndrome , *LOW density lipoproteins , *ANTICHOLESTEREMIC agents , *DRUG efficacy , *ADULTS , *PATIENTS , *MEDICAL care - Abstract
Patients with acute coronary syndrome are recommended for early aggressive low-density lipoprotein (LDL) cholesterol–lowering therapy. The LUNAR study compared the efficacy of rosuvastatin with that of atorvastatin in decreasing LDL cholesterol in patients with acute coronary syndrome. Adult patients with coronary artery disease who were hospitalized for an acute coronary syndrome within 48 hours of first symptoms were randomized (n = 825) to an open-label, once-daily treatment with rosuvastatin 20 mg (RSV20), rosuvastatin 40 mg (RSV40), or atorvastatin 80 mg (ATV80) for 12 weeks. Patients were evaluated at weeks 2, 6, and 12. The primary end point was treatment efficacy in lowering LDL cholesterol averaged over 6 to 12 weeks. Changes in other lipoproteins, including high-density lipoprotein (HDL) cholesterol, and safety were evaluated. Analysis of covariance was used to compare least squares mean differences between each rosuvastatin treatment arm and the atorvastatin arm. The efficacy of RSV40 in lowering LDL cholesterol was significantly greater than that of ATV80 (46.8% vs 42.7% decrease, p = 0.02). LDL cholesterol lowering by RSV20 was similar to that by ATV80. Increases in HDL cholesterol were significantly greater with RSV40 (11.9%, p <0.001) and RSV20 (9.7%, p <0.01) than with ATV80 (5.6%). RSV40 was also significantly more effective than ATV80 in improving most other secondary efficacy variables, whereas the effects of RSV20 on these parameters were generally similar to those of ATV80. All 3 treatments were generally well tolerated over 12 weeks. In conclusion, results from the LUNAR study show that RSV40 more effectively decreased LDL cholesterol, increased HDL cholesterol, and improved other blood lipid parameters than ATV80 in patients with acute coronary syndrome. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
5. Transatlantic similarities and differences in major natural history endpoints of heart failure after acute myocardial infarction: A propensity-matched study of the EPHESUS trial
- Author
-
Pitt, Bertram, Zannad, Faiez, Gheorghiade, Mihai, Martínez, Felipe, Love, Thomas E., Daniel, Casey, and Ahmed, Ali
- Subjects
- *
HEART failure , *HEALTH outcome assessment , *MYOCARDIAL infarction , *MORTALITY , *HOSPITAL care , *CARDIOVASCULAR diseases , *MEDICAL care , *PATIENTS - Abstract
Abstract: Background: Transatlantic differences in outcomes in heart failure after acute myocardial infarction (AMI) have not been examined in propensity-matched studies. Methods: In the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS), there were significant imbalances in baseline characteristics between patients from North America (n =858) and Europe (n =4646). Propensity scores for North America, calculated for each patient using 64 baseline characteristics, were used to assemble 298 pairs of patients who were well balanced on all measured baseline characteristics. Matched Cox regression models were used to estimate transatlantic differences in outcomes. Results: There was no transatlantic difference in all-cause mortality during 16 months of mean follow-up of (matched hazard ratio {HR}, 1.00; 95% confidence interval {CI}, 0.64–1.57; P =1.000). All-cause hospitalization occurred in 175 (rate, 8974/10,000 person-years) and 137 (rate, 5249/10,000 person-years) patients respectively from North America and Europe (matched HR when North America was compared with Europe, 1.89; 95% CI, 1.41–2.52; P <0.0001). Matched HRs (95% CIs) for cardiovascular and non-cardiovascular hospitalization for North America were respectively 1.35 (0.92–1.97; P =0.125) and 1.89 (1.31–2.72; P <0.0001). Among 5504 pre-match patients, unadjusted, multivariable-adjusted, and propensity-adjusted HRs for all-cause hospitalization for North America were 1.52 (95% CI, 1.38–1.68; P <0.0001), 1.16 (95% CI, 1.02–1.31; P =0.020), 1.41 (95% CI, 1.17–1.70; P <0.0001). Conclusion: Despite major transatlantic differences in baseline characteristics, there was no difference in post-AMI mortality. The increased non-cardiovascular hospitalization in North America may in part be due to transatlantic differences in patient preferences and access to care. [Copyright &y& Elsevier]
- Published
- 2010
- Full Text
- View/download PDF
6. MRAs in Patients With AMI Without Early Evidence of Heart Failure: Time for Reappraisal?
- Author
-
Pitt, Bertram
- Subjects
- *
MYOCARDIAL infarction , *MINERALOCORTICOID receptors , *HEART failure patients , *CARDIAC arrest , *PATIENTS , *SPIRONOLACTONE , *ALDOSTERONE antagonists , *HEART ventricle diseases , *LEFT heart ventricle , *HEART failure , *THERAPEUTICS ,CARDIOVASCULAR disease related mortality - Published
- 2016
- Full Text
- View/download PDF
7. Low serum magnesium and cardiovascular mortality in chronic heart failure: A propensity-matched study
- Author
-
Adamopoulos, Chris, Pitt, Bertram, Sui, Xuemei, Love, Thomas E., Zannad, Faiez, and Ahmed, Ali
- Subjects
- *
MAGNESIUM metabolism , *SERUM , *HEART failure patients , *CHRONIC diseases , *ARRHYTHMIA , *LOGISTIC regression analysis ,CARDIOVASCULAR disease related mortality - Abstract
Abstract: Background: Low serum magnesium levels may cause fatal ventricular arrhythmias. However, their long-term effects on mortality and morbidity in chronic heart failure patients are relatively unknown. Methods: We studied 1569 chronic systolic and diastolic heart failure patients with normal sinus rhythm who participated in the Digitalis Investigation Group trial and had serum magnesium data available at one month. Of these, 741 patients had normal (>2 mEq/L) and 828 had low (≤2 mEq/L) serum magnesium levels. Propensity scores for having low serum magnesium levels were calculated for each patient using a non-parsimonious multivariable logistic regression model, and were used to match 560 (76%) low-magnesium patients with 560 normal-magnesium patients. Effects of low-magnesium on mortality and hospitalization during a mean follow-up of 36 months were assessed using matched Cox regression analyses. Results: All-cause mortality occurred in 156 (rate, 915/10,000 person-years) normal- magnesium and 171 (rate, 1034/10,000 person-years) low-magnesium patients, respectively, during 1704 and 1653 years of follow-up (hazard ratio, 1.23; 95% confidence interval, 0.97–1.57; p =0.089). Cardiovascular mortality occurred in 110 (rate, 646/10,000 person-years) normal-magnesium and 133 (rate, 805/10,000 person-years) low-magnesium patients (hazard ratio, 1.38, 95% confidence interval, 1.04–1.83, p =0.024). Hazard ratios and 95% confidence intervals for all-cause and cardiovascular hospitalizations were respectively 1.18 (0.99–1.42; p =0.068) and 1.14 (0.94–1.39; p =0.182). Conclusions: In a propensity-matched population of ambulatory chronic heart failure patients who were balanced in all measured baseline covariates, serum magnesium level 2 mEq/L or less was associated with increased cardiovascular mortality, but had no association with cardiovascular hospitalization. [Copyright &y& Elsevier]
- Published
- 2009
- Full Text
- View/download PDF
8. A History of Systemic Hypertension and Incident Heart Failure Hospitalization in Patients With Acute Myocardial Infarction and Left Ventricular Systolic Dysfunction
- Author
-
Ahmed, Ali and Pitt, Bertram
- Subjects
- *
HYPERTENSION , *MYOCARDIAL infarction complications , *CORONARY disease , *HOSPITAL care , *REGRESSION analysis , *HEART failure , *CARDIAC contraction , *PATIENTS - Abstract
The associations of a history of hypertension with subsequent outcomes after acute myocardial infarction have not been examined in propensity-matched studies. Of the 6,632 patients with acute myocardial infarctions and left ventricular systolic dysfunction in the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS), 4,407 had histories of hypertension. Propensity scores for a history of hypertension, estimated for each patient using 64 baseline characteristics, were used to match 1,990 pairs of patients with and without hypertension. Matched Cox regression models were used to estimate associations between hypertension and outcomes during a mean of 16 months of follow-up. Heart failure (HF) hospitalization occurred in 11.9% and 8.8% of patients, respectively, with and without hypertension (hazard ratio [HR] for hypertension vs no hypertension 1.36, 95% confidence interval [CI] 1.10 to 1.68, p = 0.004). The association between a history of hypertension and HF hospitalization was significant only in patients without previous HF (n = 3,495, HR 1.48, 95% CI 1.18 to 1.84, p = 0.001), but not in those with previous HF (n = 485, HR 1.09, 95% CI 0.73 to 1.62, p = 0.688, p for interaction = 0.179). A history of hypertension was not associated with all-cause mortality (HR 1.02, 95% CI 0.86 to 1.22, p = 0.790) or cardiovascular hospitalization (HR 1.08, 95% CI 0.92 to 1.27, p = 0.339). In conclusion, a history of hypertension was associated with subsequent HF hospitalization after acute myocardial infarction, especially in patients without histories of HF, suggesting that hypertension increased the risk for hospitalization with incident HF but did not affect hospitalization for worsening HF symptoms in those with prevalent HF. [Copyright &y& Elsevier]
- Published
- 2009
- Full Text
- View/download PDF
9. Lipid Levels After Acute Coronary Syndromes
- Author
-
Pitt, Bertram, Loscalzo, Joseph, Yčas, Joseph, and Raichlen, Joel S.
- Subjects
- *
LIPIDS , *SERUM , *CORONARY disease , *MYOCARDIAL infarction - Abstract
Objectives: This analysis from the LUNAR (Limiting UNdertreatment of lipids in ACS with Rosuvastatin) study assessed lipid changes 1 to 4 days after onset of acute coronary syndromes (ACS), before initiation of study treatment. Background: Early studies indicated that cholesterol levels decrease significantly after ACS. However, most studies were small or did not measure low-density lipoprotein cholesterol (LDL-C) directly, and many used nonfasting or retrospective data. More recent studies suggest less pronounced changes in cholesterol levels after ACS. Methods: The LUNAR trial is a prospective, multicenter, randomized, open-label study in adults hospitalized for acute ST-segment elevation myocardial infarction (STEMI), non-STEMI, or unstable angina (UA). Blood samples were taken at median times after onset of ACS symptoms of 26 h (Day 1, fasting or nonfasting sample), 43 h (Day 2, fasting sample), and 84 h (Day 4, fasting sample) for direct measurement of serum lipid levels before study treatments were started. Results: Of 507 patients available for analysis, 212 were admitted for STEMI, 176 for non-STEMI, and 119 for UA. The LDL-C levels decreased in the 24 h after admission (from 136.2 to 133.5 mg/dl), followed by an increase over the subsequent 2 days (to 141.8 mg/dl). These changes did not seem to be clinically meaningful. Similar changes were observed for total cholesterol and smaller changes for high-density lipoprotein cholesterol; fasting triglyceride levels did not change. Conclusions: Mean lipid levels vary relatively little in the 4 days after an ACS and can be used to guide selection of lipid-lowering medication. (LUNAR Phase IIIb Study Comparing Rosuvastatin and Atorvastatin in Subjects With Acute Coronary Syndromes; NCT00214630) [Copyright &y& Elsevier]
- Published
- 2008
- Full Text
- View/download PDF
10. Effects of digoxin at low serum concentrations on mortality and hospitalization in heart failure: A propensity-matched study of the DIG trial
- Author
-
Ahmed, Ali, Pitt, Bertram, Rahimtoola, Shahbudin H., Waagstein, Finn, White, Michel, Love, Thomas E., and Braunwald, Eugene
- Subjects
- *
HEART diseases , *MORTALITY , *SERUM , *BLOOD plasma - Abstract
Abstract: Background: In heart failure (HF), digoxin at low serum digoxin concentrations (SDC) reduces all-cause mortality and HF hospitalizations. However, the effects of digoxin on other cause-specific outcomes have not been studied in a propensity-matched cohort. Methods: The Digitalis Investigation Group trial, conducted during 1991–1993, enrolled 7788 ambulatory chronic HF patients. This analysis focuses on 4843 patients: 982 receiving digoxin with low (0.5–0.9 ng/ml) SDC at one month, and 3861 receiving placebo and alive at one month. Propensity scores for low SDC, calculated using a non-parsimonious multivariable logistic regression model, were used to match 982 low-SDC patients with 982 placebo patients. Matched Cox regression analyses were used to determine the effect of digoxin at low SDC on outcomes. Results: All-cause mortality occurred in 315 placebo (rate, 1071/10,000 person-years) and 288 low-SDC digoxin (rate, 871/10,000 person-years) patients, respectively, during 2940 and 3305 years of follow up (hazard ratio {HR}, 0.81, 95% confidence interval {CI}, 0.68–0.98; p =0.028). Cardiovascular hospitalizations occurred in 493 placebo (2359/10,000 person-year) and 471 low-SDC digoxin (1963/10,000 person-year) patients, respectively during 2090 and 2399 years of follow up (HR, 0.82, 95% CI, 0.70–0.95; P =0.010). Low-SDC digoxin to placebo HR (95%CI) for HF mortality and HF hospitalizations were respectively, 0.65 (0.45–0.92; P =0.015) and 0.63 (0.52–0.77; P <0.0001). Low-dose digoxin (≤0.125 mg/day) was the strongest independent predictor of low SDC (adjusted odd ratio, 2.07, 95% CI 1.54–2.80). Conclusions: Digoxin at low SDC significantly reduced mortality and hospitalizations in ambulatory chronic systolic and diastolic HF patients. [Copyright &y& Elsevier]
- Published
- 2008
- Full Text
- View/download PDF
11. Improving Outcomes in Post–Acute Myocardial Infarction Heart Failure: Incorporation of Aldosterone Blockade into Combination Therapy to Optimize Neurohormonal Blockade
- Author
-
Pitt, Bertram, Fonarow, Gregg C., Gheorghiade, Mihai, Deedwania, Prakash C., and Duprez, Daniel A.
- Subjects
- *
MYOCARDIAL infarction , *CARDIAC arrest , *CORONARY disease , *ACE inhibitors - Abstract
Although angiotensin-converting enzyme (ACE) inhibitors, angiotensin II receptor blockers (ARBs), and β-blockers have been proved to reduce mortality in patients with heart failure post–acute myocardial infarction (AMI), studies show that these agents are consistently underused in this population. Further, morbidity and mortality remain high even when standard-of-care therapies are applied. Thus, new strategies have been sought to better counteract the maladaptive effects of neurohormonal stimulation in post-AMI heart failure. The Eplerenone Post–Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS) demonstrated that the selective aldosterone blocker eplerenone, when used in addition to standard therapy, results in significant incremental improvements in survival and morbidity and is safe and well tolerated in this setting. Based on this, major therapeutic guidelines in the United States and Europe now strongly recommend that all eligible patients with concomitant heart failure post-AMI be treated with an aldosterone blocker in addition to an ACE inhibitor (or an ARB) and a β-blocker. To achieve needed improvements in outcomes in this population, early and consistent initiation of these evidence-based, guideline-recommended therapies in all eligible patients is crucial. [Copyright &y& Elsevier]
- Published
- 2006
- Full Text
- View/download PDF
12. Eplerenone Reduces Mortality 30 Days After Randomization Following Acute Myocardial Infarction in Patients With Left Ventricular Systolic Dysfunction and Heart Failure
- Author
-
Pitt, Bertram, White, Harvey, Nicolau, Jose, Martinez, Felipe, Gheorghiade, Mihai, Aschermann, Michael, van Veldhuisen, Dirk J., Zannad, Faiez, Krum, Henry, Mukherjee, Robin, and Vincent, John
- Subjects
- *
MYOCARDIAL infarction , *MORTALITY , *CORONARY disease , *HEART failure - Abstract
Objectives: This study sought to assess the impact of the selective aldosterone blocker eplerenone on mortality 30 days after randomization in patients after acute myocardial infarction (AMI) with a left ventricular ejection fraction (LVEF) ≤40% and clinical signs of heart failure. Background: In the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS), eplerenone reduced all-cause mortality by 15% (p = 0.008) over a mean follow-up of 16 months when used with standard therapy in patients after AMI with an LVEF ≤40% and clinical signs of heart failure. Methods: We analyzed the effect of eplerenone 25 mg/day initiated 3 to 14 days after AMI (mean, 7.3 days) on the co-primary end points of time to death from any cause and the composite end point of time to death from cardiovascular (CV) causes or hospitalization for CV events, and the secondary end points of CV mortality, sudden cardiac death, and fatal/nonfatal hospitalization for heart failure, after 30 days of therapy in the EPHESUS trial. Results: At 30 days after randomization, eplerenone reduced the risk of all-cause mortality by 31% (3.2% vs. 4.6% in eplerenone and placebo-treated patients, respectively; p = 0.004) and reduced the risk of CV mortality/CV hospitalization by 13% (8.6% vs. 9.9% in eplerenone and placebo-treated patients, respectively; p = 0.074). Eplerenone also reduced the risk of CV mortality by 32% (p = 0.003) and the risk of sudden cardiac death by 37% (p = 0.051). Conclusions: Eplerenone 25 mg/day significantly reduced all-cause mortality 30 days after randomization (when initiated at a mean of 7.3 days after AMI) in addition to conventional therapy in patients with an LVEF ≤40% and signs of heart failure. Based on its early survival benefit, eplerenone should be administered in the hospital after AMI. [Copyright &y& Elsevier]
- Published
- 2005
- Full Text
- View/download PDF
13. Generic drugs in cardiology: will they reduce health care costs?
- Author
-
Pitt, Bertram
- Subjects
- *
GENERIC drugs , *CARDIOLOGY , *MEDICAL care costs , *PHYSICIANS - Abstract
The introduction of generic drugs should lower health care costs by reducing the price of drugs. The realization of this goal may, however, not be fully achieved: generic drugs may be underused or misused in comparison to prescription drugs because of a lack of ongoing postgraduate physician education. More importantly, there is little incentive to explore new indications for soon-to-be generic drugs and drugs that are already generic. The failure to explore new indications for soon-to-be and existing generic drugs may result in a missed opportunity to further reduce health care costs. Thus, the apparent savings resulting from the introduction of generic drugs may not be fully realized unless the government and other third-party payers take a more active role in postgraduate drug education and investigation. [Copyright &y& Elsevier]
- Published
- 2004
- Full Text
- View/download PDF
14. Effect of aldosterone blockade in patients with systolic left ventricular dysfunction: implications of the RALES and EPHESUS studies
- Author
-
Pitt, Bertram
- Subjects
- *
ALDOSTERONE , *MINERALOCORTICOIDS , *CARDIAC arrest , *HYPERTENSION - Abstract
Aldosterone blockade has been shown to be effective in reducing total mortality as well as hospitalization for heart failure in patients with systolic left ventricular dysfunction (SLVD) due to chronic heart failure and in patients with SLVD post acute myocardial infarction. The evidence for the effectiveness of aldosterone blockade in chronic heart failure comes from the randomized aldactone evaluation study (RALES) while that for patients post infarction from the eplerenone post acute myocardial infarction efficacy and survival study (EPHESUS). These studies suggest that mineralocorticoid receptor activation remains important despite the use of an angiotensin converting enzyme-inhibitor/angiotensin receptor blocking (ARB) agent and a beta blocker.Increasing evidence suggest that aldosterone blockade has important effects not only on the kidney but on ventricular remodeling, myocardial fibrosis, autonomic balance, fibrinolysis, oxidative stress, and activation of the NF-κB and AP-1 signaling pathways. The results of these studies in patients with SLVD has important implications not only for patients with chronic heart failure and post infarction but also for the therapy of patients with essential hypertension and other cardiovascular diseases. [Copyright &y& Elsevier]
- Published
- 2004
- Full Text
- View/download PDF
15. The QUinapril Ischemic Event Trial (QUIET): evaluation of chronic ACE inhibitor therapy in patients with ischemic heart disease and preserved left ventricular function.
- Author
-
Pitt, Bertram, O'Neill, Blair, Feldman, Robert, Ferrari, Roberto, Schwartz, Leonard, Mudra, Harald, Bass, Theodore, Pepine, Carl, Texter, Michele, Haber, Harry, Uprichard, Andrew, Hemphill, Linda Cashin, Lees, Robert S., Pitt, B, O'Neill, B, Feldman, R, Ferrari, R, Schwartz, L, Mudra, H, and Bass, T
- Subjects
- *
ANGIOTENSIN converting enzyme , *CORONARY heart disease treatment - Abstract
Angiotensin-converting enzyme inhibitors improve endothelial function, inhibit experimental atherogenesis, and decrease ischemic events. The Quinapril Ischemic Event Trial was designed to test the hypothesis that quinapril 20 mg/day would reduce ischemic events (the occurrence of cardiac death, resuscitated cardiac arrest, nonfatal myocardial infarction, coronary artery bypass grafting, coronary angioplasty, or hospitalization for angina pectoris) and the angiographic progression of coronary artery disease in patients without systolic left ventricular dysfunction. A total of 1,750 patients were randomized to quinapril 20 mg/day or placebo and followed a mean of 27 +/- 0.3 months. The 38% incidence of ischemic events was similar for both groups (RR 1.04; 95% confidence interval 0.89 to 1.22; p = 0.6). There was also no significant difference in the incidence of patients having angiographic progression of coronary disease (p = 0.71). The rate of development of new coronary lesions was also similar in both groups (p = 0.35). However, there was a difference in the incidence of angioplasty for new (previously unintervened) vessels (p = 0.018). Quinapril was well tolerated in patients after angioplasty with normal left ventricular function. Quinapril 20 mg did not significantly affect the overall frequency of clinical outcomes or the progression of coronary atherosclerosis. However, the absence of the demonstrable effect of quinapril may be due to several limitations in study design. [ABSTRACT FROM AUTHOR]
- Published
- 2001
- Full Text
- View/download PDF
16. Potential repurposing of the HDAC inhibitor valproic acid for patients with COVID-19.
- Author
-
Pitt, Bertram, Sutton, Nadia R., Wang, Zhong, Goonewardena, Sascha N., and Holinstat, Michael
- Subjects
- *
SARS-CoV-2 , *VALPROIC acid , *COVID-19 , *HISTONE deacetylase inhibitors - Abstract
There is a need for therapeutic approaches to prevent and mitigate the effects of Coronavirus Disease (2019) (COVID-19). The histone deacetylase (HDAC) inhibitor valproic acid, which has been available for the therapy of epilepsy for many years, is a drug that could be repurposed for patients with severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection. This article will review the reasons to consider valproic acid as a potential therapeutic to prevent severe COVID-19. Valproic acid could reduce angiotensin-converting enzyme 2 and transmembrane serine protease 2 expression, required for SARS-CoV-2 viral entry, and modulate the immune cellular and cytokine response to infection, thereby reducing end-organ damage. The combined anti-thrombotic, anti-platelet, and anti-inflammatory effects of valproic acid suggest it could be a promising therapeutic target for COVID-19. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
17. Cardiovascular-Kidney-Metabolic Overlap in Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Trial-Level Analysis.
- Author
-
Ostrominski, John W., Claggett, Brian L., Miao, Zi Michael, Mc Causland, Finnian R., Anand, Inder S., Desai, Akshay S., Jhund, Pardeep S., Lam, Carolyn S.P., Pfeffer, Marc A., Pitt, Bertram, Zannad, Faiez, Zile, Michael R., Bomfim Wirtz, Antonieta, Lay-Flurrie, James, Viswanathan, Prabhakar, McMurray, John J.V., Solomon, Scott D., and Vaduganathan, Muthiah
- Subjects
- *
HEART failure , *VENTRICULAR ejection fraction , *CARDIOVASCULAR diseases , *KIDNEY diseases - Published
- 2024
- Full Text
- View/download PDF
18. Mineralocorticoid Receptor Antagonists in Patients With Heart Failure and Impaired Renal Function.
- Author
-
Matsumoto, Shingo, Henderson, Alasdair D., Shen, Li, Yang, Mingming, Swedberg, Karl, Vaduganathan, Muthiah, van Veldhuisen, Dirk J., Solomon, Scott D., Pitt, Bertram, Zannad, Faiez, Jhund, Pardeep S., and McMurray, John J.V.
- Subjects
- *
MINERALOCORTICOID receptors , *HEART failure patients , *KIDNEY physiology , *KIDNEY failure , *TERMINATION of treatment - Abstract
Kidney dysfunction often leads to reluctance to start or continue life-saving heart failure (HF) therapy. This study sought to examine the efficacy and safety of mineralocorticoid receptor antagonists (MRAs) in patients with HF with reduced ejection fraction experiencing significant kidney dysfunction. We pooled individual patient data from the RALES (Randomized Aldactone Evaluation Study) and EMPHASIS-HF (Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure) trials. The association between MRA treatment and outcomes was assessed according to whether the estimated glomerular filtration rate (eGFR) declined to <30 mL/min/1.73 m2 or not. The primary outcome was cardiovascular death or HF hospitalization. Among 4,355 patients included, 295 (6.8%) experienced a deterioration of eGFR after randomization to <30 mL/min/1.73 m2. These patients had more impaired baseline cardiac and kidney function (eGFR 47.3 ± 13.4 mL/min/1.73 m2 vs 70.5 ± 21.8 mL/min/1.73 m2) and had a higher risk of the primary outcome than patients without eGFR deterioration (HR: 2.49; 95% CI: 2.01-3.08; P < 0.001). However, the risk reduction in the primary outcome with MRA therapy was similar in those who experienced a decrease in eGFR to <30 mL/min/1.73 m2 (HR: 0.65; 95% CI: 0.43-0.99) compared with those who did not (HR: 0.63; 95% CI: 0.56-0.71) (P interaction = 0.87). In patients with a decrease in eGFR to <30 mL/min/1.73 m2, 21 fewer individuals (per 100 person-years) experienced the primary outcome with MRA treatment, vs placebo, compared with an excess of 3 more patients with severe hyperkalemia (>6.0 mmol/L). Because patients experiencing a decrease in eGFR to <30 mL/min/1.73 m2 are at very high risk, the absolute risk reduction with an MRA in these patients is large and this decline in eGFR should not automatically lead to treatment discontinuation. [Display omitted] [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
19. Baseline clinical and angiographic data in the Quinapril Ischemic Event (QUIET) trial.
- Author
-
Lees, Robert S. and Pitt, Bertram
- Subjects
- *
QUINAPRIL , *PHYSIOLOGY - Abstract
Studies the clinical and angiographic characteristics of patients undergoing a Quinapril Ischemic Event Trial (QUIET). Purpose of QUIET; Therapeutic effects of quinapril; Utilization of angiotensin-converting enzyme inhibition in the treatment of left ventricular systolic dysfunction.
- Published
- 1996
- Full Text
- View/download PDF
20. Coronary angiographic changes in patients with cardiac events in the Prospective Randomized Evaluation of the Vascular Effects of Norvasc Trial (PREVENT)
- Author
-
John Mancini, G.B. and Pitt, Bertram
- Published
- 2002
- Full Text
- View/download PDF
21. The current best drug treatment for hypertensive heart failure with preserved ejection fraction.
- Author
-
Rist, Aurora, Sevre, Kaja, Wachtell, Kristian, Devereux, Richard B., Aurigemma, Gerard P., Smiseth, Otto A., Kjeldsen, Sverre E., Julius, Stevo, Pitt, Bertram, Burnier, Michel, Kreutz, Reinhold, Oparil, Suzanne, Mancia, Giuseppe, and Zannad, Faiez
- Subjects
- *
HEART failure , *SODIUM-glucose cotransporter 2 inhibitors , *VENTRICULAR ejection fraction , *ANGIOTENSIN-receptor blockers , *ACE inhibitors , *ANGIOTENSIN receptors - Abstract
• Most patients (about 90 %) who develop heart failure (HF) have hypertension. • All drugs used in the treatment of heart failure lower blood pressure. • Heart failure patients in general have reduced systolic function. • The totality of evidence indicates no difference in drug treatment related to EF. • RASi or ARNI, MRA, beta-blocker and SGLT2i plus diuretics are used to treat HF patients. More than 90 % of patients developing heart failure (HF) have hypertension. The most frequent concomitant conditions are type-2 diabetes mellitus, obesity, atrial fibrillation, and coronary disease. HF outcome research focuses on decreasing mortality and preventing hospitalization for worsening HF syndrome. All drugs that decrease these HF endpoints lower blood pressure. Current drug treatments for HF are (i) angiotensin-converting enzyme inhibitors, angiotensin receptor blockers or angiotensin receptor neprilysin inhibitors, (ii) selected beta-blockers, (iii) steroidal and non-steroidal mineralocorticoid receptor antagonists, and (iv) sodium-glucose cotransporter 2 inhibitors. For various reasons, these drug treatments were first studied in HF patients with a reduced ejection fraction (HFrEF). Subsequently, they have been investigated in HF patients with a preserved left ventricular ejection fraction (LVEF, HFpEF) of mostly hypertensive etiology, and with modest benefits largely assessed on top of background treatment with the drugs already proven effective in HFrEF. Additionally, diuretics are given on symptomatic indications. Patients with HFpEF may have diastolic dysfunction but also systolic dysfunction visualized by lack of longitudinal shortening. Considering the totality of evidence and the overall need for antihypertensive treatment and/or treatment of hypertensive complications in almost all HF patients, the principal drug treatment of HF appears to be the same regardless of LVEF. Rather than LVEF-guided treatment of HF, treatment of HF should be directed by symptoms (related to the level of fluid retention), signs (tachycardia), severity (NYHA functional class), and concomitant diseases and conditions. All HF patients should be given all the drug classes mentioned above if well tolerated. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
22. Overview of Angiotensin II-Receptor Antagonists.
- Author
-
Pitt, Bertram and Konstam, Marvin A.
- Subjects
- *
ANGIOTENSIN-receptor blockers , *HYPERTENSION , *THERAPEUTICS , *HEART failure treatment , *ANGIOTENSIN converting enzyme , *BRADYKININ , *PHYSIOLOGY - Abstract
The article focuses on a study on impact of angiotensin II-receptor blockers (ARBs) on hypertension and heart failure treatment. Topics discussed include angiotensin-converting enzyme (ACE) inhibitors' impact on renin-angiotensin system, angiotensin II type 1 (AT1) receptors activation by ARBs, bradykinin degradation regulated by angiotensin II and ARBs, blood pressure-lowering effect associated with ARBs and the ACE inhibitor Enalapril and angiotensin II effect blocked by the AT1 receptor.
- Published
- 1998
- Full Text
- View/download PDF
23. Finerenone Reduces New-Onset Atrial Fibrillation in Patients With Chronic Kidney Disease and Type 2 Diabetes.
- Author
-
Filippatos, Gerasimos, Bakris, George L., Pitt, Bertram, Agarwal, Rajiv, Rossing, Peter, Ruilope, Luis M., Butler, Javed, Lam, Carolyn S.P., Kolkhof, Peter, Roberts, Luke, Tasto, Christoph, Joseph, Amer, Anker, Stefan D., and FIDELIO-DKD Investigators
- Subjects
- *
TYPE 2 diabetes , *CHRONIC kidney failure , *ATRIAL fibrillation , *DIABETIC nephropathies , *CHRONICALLY ill , *HEART failure , *ATRIAL fibrillation prevention , *RESEARCH , *HETEROCYCLIC compounds , *RESEARCH methodology , *DISEASE incidence , *MEDICAL cooperation , *EVALUATION research , *COMPARATIVE studies , *ALDOSTERONE antagonists , *DISEASE complications ,CHRONIC kidney failure complications - Abstract
Background: Patients with chronic kidney disease (CKD) and type 2 diabetes (T2D) are at risk of atrial fibrillation or flutter (AFF) due to cardiac remodeling and kidney complications. Finerenone, a novel, selective, nonsteroidal mineralocorticoid receptor antagonist, inhibited cardiac remodeling in preclinical models.Objectives: This work aims to examine the effect of finerenone on new-onset AFF and cardiorenal effects by history of AFF in the Finerenone in Reducing Kidney Failure and Disease Progression in Diabetic Kidney Disease (FIDELIO-DKD) study.Methods: Patients with CKD and T2D were randomized (1:1) to finerenone or placebo. Eligible patients had a urine albumin-to-creatinine ratio ≥30 to ≤5,000 mg/g, an estimated glomerular filtration rate (eGFR) ≥25 to <75 ml/min/1.73 m2 and received optimized doses of renin-angiotensin system blockade. Effect on new-onset AFF was evaluated as a pre-specified outcome adjudicated by an independent cardiologist committee. The primary composite outcome (time to first onset of kidney failure, a sustained decrease of ≥40% in eGFR from baseline, or death from renal causes) and key secondary outcome (time to first onset of cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, or hospitalization for heart failure) were analyzed by history of AFF.Results: Of 5,674 patients, 461 (8.1%) had a history of AFF. New-onset AFF occurred in 82 (3.2%) patients on finerenone and 117 (4.5%) patients on placebo (hazard ratio: 0.71; 95% confidence interval: 0.53-0.94; p = 0.016). The effect of finerenone on primary and key secondary kidney and cardiovascular outcomes was not significantly impacted by baseline AFF (interaction p value: 0.16 and 0.85, respectively).Conclusions: In patients with CKD and T2D, finerenone reduced the risk of new-onset AFF. The risk of kidney or cardiovascular events was reduced irrespective of history of AFF at baseline. (EudraCT 2015-000990-11 [A randomized, double-blind, placebo-controlled, parallel-group, multicenter, event-driven Phase III study to investigate the efficacy and safety of finerenone, in addition to standard of care, on the progression of kidney disease in subjects with type 2 diabetes mellitus and the clinical diagnosis of diabetic kidney disease]; Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and Diabetic Kidney Disease [FIDELIO-DKD]; NCT02540993). [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
24. Efficacy of Sotagliflozin in Adults With Type 2 Diabetes in Relation to Baseline Hemoglobin A1c.
- Author
-
Aggarwal, Rahul, Bhatt, Deepak L., Szarek, Michael, Cannon, Christopher P., McGuire, Darren K., Inzucchi, Silvio E., Lopes, Renato D., Davies, Michael J., Banks, Phillip, Pitt, Bertram, and Steg, Philippe Gabriel
- Subjects
- *
TYPE 2 diabetes , *GLYCOSYLATED hemoglobin , *PROPORTIONAL hazards models , *HEMOGLOBINS , *ADULTS - Abstract
The SCORED (Effect of Sotagliflozin on Cardiovascular and Renal Events in Patients with Type 2 Diabetes and Moderate Renal Impairment Who Are at Cardiovascular Risk) and SOLOIST-WHF (Effect of Sotagliflozin on Cardiovascular Events in Patients with Type 2 Diabetes Post Worsening Heart Failure) trials demonstrated that sotagliflozin, an SGLT1 and SGLT2 inhibitor, improves outcomes in individuals with type 2 diabetes who have heart failure (HF) or kidney disease. We assessed the efficacy of sotagliflozin on HF clinical outcomes in individuals with differing baseline glycosylated hemoglobin (HbA1c) levels. We included all adults from SCORED and SOLOIST-WHF. The primary outcome was a composite of cardiovascular death, hospitalizations for HF, and urgent visits for HF. The efficacy of sotagliflozin compared with placebo was evaluated by baseline HbA1c using competing-risk marginal proportional hazards models. We identified 11,744 adults. Individuals with HbA1c ≤7.5% experienced the primary outcome at a lower rate in the sotagliflozin group (11.2 per 100 person-years) than the placebo group (15.5 per 100 person-years) (HR: 0.73; 95% CI: 0.57-0.93). Similarly, individuals with HbA1c of 7.6% to 9.0% experienced the primary outcome at a lower rate in the sotagliflozin group (7.3 per 100 person-years) than the placebo group (9.4 per 100 person-years) (HR: 0.77; 95% CI: 0.63-0.96). These findings were also consistent among individuals with HbA1c >9.0%, with a primary outcome rate in the sotagliflozin group (7.8 per 100 person-years) that was lower than the placebo group (11.6 per 100 person-years) (HR: 0.65; 95% CI: 0.50-0.84). The efficacy of sotagliflozin was consistent by baseline HbA1c level (P for interaction = 0.58). In individuals with type 2 diabetes and either HF or kidney disease, sotagliflozin reduced HF outcomes irrespective of baseline HbA1c. [Display omitted] [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
25. MY APPROACH to patients with heart failure and a normal ejection fraction.
- Author
-
Pitt, Bertram
- Subjects
- *
HEART disease related mortality , *HEART failure patients , *LEFT heart ventricle , *EPIDEMIOLOGY , *MEDICAL research - Published
- 2015
- Full Text
- View/download PDF
26. Underutilization of Mineralocorticoid Antagonists in Patients With Heart Failure With Reduced Ejection Fraction.
- Author
-
Matsumoto, Shingo, Kondo, Toru, Jhund, Pardeep S., Campbell, Ross T., Swedberg, Karl, van Veldhuisen, Dirk J., Pocock, Stuart J., Pitt, Bertram, Zannad, Faiez, and McMurray, John J.V.
- Subjects
- *
HEART failure patients , *VENTRICULAR ejection fraction , *MINERALOCORTICOID receptors - Published
- 2023
- Full Text
- View/download PDF
27. TREATMENT WITH PATIROMER DECREASES ALDOSTERONE IN PATIENTS WITH HEART FAILURE, CHRONIC KIDNEY DISEASE, AND HYPERKALEMIA ON RAAS INHIBITORS.
- Author
-
Pitt, Bertram, Gross, Coleman, Mayo, Martha, Garza, Dahlia, Yuan, Jinwei, Wilson, Daniel, and Weir, Matthew
- Subjects
- *
HEART failure patients , *THERAPEUTICS , *KIDNEY diseases , *ALDOSTERONE antagonists , *HYPERKALEMIA , *CHRONIC diseases - Published
- 2017
- Full Text
- View/download PDF
28. Mineralocorticoid receptor antagonists in patients with end-stage renal disease on chronic hemodialysis.
- Author
-
Pitt, Bertram and Rossignol, Patrick
- Published
- 2014
- Full Text
- View/download PDF
29. Mineralocorticoid Receptor Antagonists in Patients With End-Stage Renal Disease on Chronic Hemodialysis ∗.
- Author
-
Pitt, Bertram and Rossignol, Patrick
- Published
- 2014
- Full Text
- View/download PDF
30. 1-YEAR SAFETY AND EFFICACY OF PATIROMER FOR HYPERKALEMIA IN HEART FAILURE PATIENTS WITH CHRONIC KIDNEY DISEASE ON RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM INHIBITORS.
- Author
-
Pitt, Bertram, Bushinsky, David, Garza, Dahlia, Stasiv, Yuri, Mond, Charles Du, Berman, Lance, and Bakris, George
- Subjects
- *
HYPERKALEMIA , *HEART failure patients , *KIDNEY diseases , *RENIN-angiotensin system , *ENZYME inhibitors , *CLINICAL trials , *PATIENTS , *THERAPEUTICS - Published
- 2015
- Full Text
- View/download PDF
31. Time to Benefit With Sotagliflozin in Patients With Worsening Heart Failure.
- Author
-
Verma, Subodh, Bhatt, Deepak L., Dhingra, Nitish K., Steg, Ph. Gabriel, Szarek, Michael, Davies, Michael, Metra, Marco, Lund, Lars H., and Pitt, Bertram
- Subjects
- *
HEART failure patients - Published
- 2023
- Full Text
- View/download PDF
32. Hyperkalemia in Heart Failure.
- Author
-
Sarwar, Chaudhry M.S., Papadimitriou, Lampros, Pitt, Bertram, Piña, Ileana, Zannad, Faiez, Anker, Stefan D., Gheorghiade, Mihai, and Butler, Javed
- Subjects
- *
ARRHYTHMIA , *RENIN-angiotensin system , *HEART failure treatment , *HYPERKALEMIA , *CYCLOSILICATES , *THERAPEUTICS , *DISEASE risk factors - Abstract
Disorders of potassium homeostasis can potentiate the already elevated risk of arrhythmia in heart failure. Heart failure patients have a high prevalence of chronic kidney disease, which further heightens the risk of hyperkalemia, especially when renin-angiotensin-aldosterone system inhibitors are used. Acute treatment for hyperkalemia may not be tolerated in the long term. Recent data for patiromer and sodium zirconium cyclosilicate, used to treat and prevent high serum potassium levels on a more chronic basis, have sparked interest in the treatment of hyperkalemia, as well as the potential use of renin-angiotensin-aldosterone system inhibitors in patients who were previously unable to take these drugs or tolerated only low doses. This review discusses the epidemiology, pathophysiology, and outcomes of hyperkalemia in heart failure; provides an overview of traditional and novel ways to approach management of hyperkalemia; and discusses the need for further research to optimally treat heart failure. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
33. A MULTICENTER STUDY OF DOSE TITRATION OF THE ORAL POTASSIUM BINDER RLY5016 TO MAINTAIN NORMAL SERUM POTASSIUM IN PATIENTS WITH HEART FAILURE AND CHRONIC KIDNEY DISEASE TREATED WITH RENIN-ANGIOTENSIN-ALDOSTERONE INHIBITORS AND/OR ?-BLOCKERS
- Author
-
Pitt, Bertram, Bushinsky, David, Halfon, Sherin, Kitzman, Dalane, Lainscak, Mitja, Mathur, Vandana, Stasiv, Yuri, and Huang, I-Zu
- Published
- 2011
- Full Text
- View/download PDF
34. Reply
- Author
-
Domanski, Michael J. and Pitt, Bertram
- Published
- 2004
- Full Text
- View/download PDF
35. High-sensitivity C-reactive protein in heart failure with preserved ejection fraction: Findings from TOPCAT.
- Author
-
Ferreira, João Pedro, Claggett, Brian L., Liu, Jiankang, Sharma, Abhinav, Desai, Akshay S., Anand, Inder S., O'Meara, Eileen, Rouleau, Jean L., De Denus, Simon, Pitt, Bertram, Pfeffer, Marc A., Zannad, Faiez, and Solomon, Scott D.
- Abstract
Inflammation plays a central role in the genesis and progression of heart failure with preserved ejection fraction (HFpEF). C-reactive protein (CRP) is widely used as means to assess systemic inflammation, and elevated levels of CRP have been associated with poor HF prognosis. Identification of chronic low-grade inflammation in outpatients can be performed measuring high-sensitivity CRP (hsCRP). The clinical characteristics and outcome associations of a pro-inflammatory state among outpatients with HFpEF requires further study. Using a biomarker subset of TOPCAT-Americas (NCT00094302), we aim to characterize HFpEF patients according to hsCRP levels and study the prognostic associations of hsCRP. hsCRP was available in a subset of 232 participants. Comparisons were performed between patients with hsCRP <2 mg/L and ≥ 2 mg/L. Cox regression models were used to study the association between hsCRP and the study outcomes. Compared to patients with hsCRP <2 mg/L (n = 89, 38%), those with hsCRP ≥2 mg/L (n = 143, 62%) had more frequent HF hospitalizations prior to randomization, chronic obstructive pulmonary disease, orthopnea, higher body mass index, and worse health-related quality-of-life. A hsCRP level ≥ 2 mg/L was associated with an increased risk of cardiovascular death and HF hospitalizations: hsCRP ≥2 mg/L vs <2 mg/L adjusted HR 2.36, 95%CI 1.27–4.38, P = 0.006. Spironolactone did not influence hsCRP levels from baseline to month 12: gMean ratio = 1.11, 95%CI 0.87–1.42, P = 0.39. A hsCRP ≥2 mg/L identified HFpEF patients with a high risk of HF events and cardiovascular mortality. Spironolactone did not influence hsCRP levels at 12 months. • Inflammation plays a central role in the progression of heart failure with preserved ejection fraction (HFpEF). • hsCRP was available in a subset of TOPCAT-Americas. Comparisons were performed between hsCRP <2 mg/L and ≥ 2 mg/L. • Patients with hsCRP ≥2 mg/L experienced an increased risk of HF events. Spironolactone did not change hsCRP levels. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
36. Spironolactone effect on circulating procollagen type I carboxy-terminal propeptide: Pooled analysis of three randomized trials.
- Author
-
Ferreira, João Pedro, Cleland, John G., Girerd, Nicolas, Rossignol, Patrick, Pellicori, Pierpaolo, Cosmi, Franco, Mariottoni, Beatrice, González, Arantxa, Diez, Javier, Solomon, Scott D., Claggett, Brian, Pfeffer, Marc A., Pitt, Bertram, Petutschnigg, Johannes, Pieske, Burkert, Edelmann, Frank, and Zannad, Faiez
- Subjects
- *
ALDOSTERONE antagonists , *COLLAGEN , *SPIRONOLACTONE , *VENTRICULAR ejection fraction , *HEART fibrosis , *HEART failure patients - Abstract
Spironolactone might improve the prognosis of patients with heart failure with preserved left ventricular ejection fraction (HFpEF), but the mechanisms by which it acts are uncertain. Serum concentrations of procollagen type I carboxy-terminal propeptide (PICP) reflect the synthesis of type I collagen and correlate well with histologically proven cardiac fibrosis. To investigate the effect of spironolactone on serum PICP concentration in patients with stage B and C HFpEF across three trials (HOMAGE, ALDO-DHF, and TOPCAT) for which measurements of serum PICP were available. Random-effects meta-analysis. A total of 1038 patients with PICP measurements available both at baseline and 9–12 months were included in this analysis: 488 (47.0%) from HOMAGE, 386 (37.2%) from ALDO-DHF, and 164 (15.8%) from TOPCAT. The median (percentile 25 – 75) serum PICP was 98 (76–128) ng/mL. Compared to placebo or usual care, administration of spironolactone for 9 to 12 months reduced serum PICP by −7.4 ng/mL, 95%CI -13.9 to −0.9, P -value =0.02. The effect was moderately heterogeneous (I2 = 64%) with the most pronounced effect seen in TOPCAT where PICP was reduced by −27.0 ng/mL, followed by HOMAGE where PICP was reduced by −8.1 ng/mL, and was least marked in ALDO-DHF where PICP changed by −2.9 ng/mL. The association between spironolactone and serum PICP was not mediated substantially by blood pressure. Spironolactone reduced serum concentrations of PICP in patients with HFpEF with different severity and stages of disease. These findings are consistent with spironolactone having an anti-fibrotic effect. • Serum concentrations of procollagen type I carboxy-terminal propeptide (PICP) reflect the synthesis of type I collagen and correlate with cardiac fibrosis. • Administration of spironolactone for 9 to 12 months reduced serum PICP by −7.4 ng/mL, 95%CI -13.9 to −0.9, P-value =0.02, in HFpEF. • The association between spironolactone and serum PICP was not mediated substantially by blood pressure, findings consistent with spironolactone having an anti-fibrotic effect. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
37. Emerging cardiovascular indications of mineralocorticoid receptor antagonists.
- Author
-
Parviz, Yasir, Iqbal, Javaid, Pitt, Bertram, Adlam, David, Al-Mohammad, Abdallah, and Zannad, Faiez
- Subjects
- *
CARDIOVASCULAR diseases , *MINERALOCORTICOID receptors , *SPIRONOLACTONE , *HEART failure , *LEFT ventricular hypertrophy - Abstract
Mineralocorticoid receptor (MR) antagonism is a well-established treatment modality for patients with hypertension, heart failure, and left ventricular systolic dysfunction (LVSD) post-myocardial infarction (MI). There are emerging data showing potential benefits of MR antagonists in other cardiovascular conditions. Studies have shown association between MR activation and the development of myocardial fibrosis, coronary artery disease, metabolic syndrome, and cerebrovascular diseases. This review examines the preclinical and clinical data of MR antagonists for novel indications including heart failure with preserved ejection fraction (HFPEF), pulmonary arterial hypertension (PAH), arrhythmia, sudden cardiac death, valvular heart disease, metabolic syndrome, renal disease, and stroke. MR antagonists are not licensed for these conditions yet; however, emerging data suggest that indication for MR antagonists are likely to broaden; further studies are warranted. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
38. Cardiac structure and function and quality of life associations in HFpEF: An analysis from TOPCAT-Americas.
- Author
-
Ferreira, João Pedro, Shah, Amil M., Claggett, Brian L., Pitt, Bertram, Lewis, Eldrin F., Solomon, Scott D., and Zannad, Faiez
- Subjects
- *
HEART failure , *HEART failure patients , *QUALITY of life , *BODY mass index , *CARDIOVASCULAR agents - Abstract
Patients with heart failure with preserved ejection fraction (HFpEF) have poor health-related quality of life (HR-QoL). However, the relationship between HR-QoL measures and the alterations of cardiac structure and function that are present in patients with HFpEF remains unknown. To study the associations between HR-QoL and echocardiographic parameters in HFpEF. Regression modelling in patients from TOPCAT-Americas who had both HR-QoL questionnaires and a baseline echocardiogram. A total of 631 patients (36% of the TOPCAT-Americas population) had both echocardiographic and HR-QoL at baseline. KCCQ-23 Overall Summary Score (OSS; 0–100 points) was negatively (higher echocardiographic values-poorer/lower HR-QoL scores) associated with left ventricular end-diastolic diameter (LVEDD: β = −3.56 [−7.00 to −0.13] points-per-1 cm, P = 0.042), interventricular septum thickness (β = −1.31 [−2.19 to −0.42] points-per-1 mm, P = 0.004), posterior wall thickness (β = −1.57 [−2.52 to −0.63] points-per-1 mm, P = 0.001 and left atrial width (β = −3.27 [−6.39 to −0.15], P = 0.040) points-per-1 cm, and positively (higher echocardiographic values-better/higher HR-QoL scores) associated with left ventricular end-diastolic volume index (LVEDVi: β = 0.23 [0.09 to 0.37] points-per-1 ml/m2, P = 0.002) and left ventricular end-systolic volume index (LVESVi: β = 0.41 [0.18 to 0.63] points-per-1 ml/m2, P < 0.001). Body mass index (BMI: β = −0.74 [−1.02 to −0.47] points-per-1Kg/m2, P < 0.001), diabetes (β = −6.01 [−10.05 to −1.97], P = 0.004), and asthma (β = −6.78 [−13.52 to −0.04], P = 0.049) were negatively associated with OSS. A similar pattern of associations was observed for KCCQ-23 Clinical Summary Score, EQ5D-VAS and NYHA class. In patients with HFpEF, HR-QoL measures were associated with cardiac structure and function alterations. Extra-cardiac factors were also associated with HR-QoL, which may influence HR-QoL results when testing cardiovascular drugs. • Patients with HFpEF have poor quality of life. • The relationship between HR-QoL measures and the alterations of cardiac structure and function remain unknown. • In TOPCAT-Americas HR-QoL was associated with cardiac structure and function alterations, particularly measures reflection cardiac mass and atrial volume. • Extra-cardiac factors were also associated with HR-QoL, which may influence HR-QoL results when testing cardiovascular drugs. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
39. BLOOD PRESSURE-INDEPENDENT EFFECTS OF MINERALOCORTICOID RECEPTOR BLOCKADE.
- Author
-
Vergara-Martel, Armando, Dazard, Jean-Eudes, Dobre, Mirela, Fares, Anas, Pereira, Gabriel Tensol Rodrigues, Conger, Heather, Dever, Ann M., Connelly, Kim, Al-Kindi, Sadeer G., Pitt, Bertram, Brook, Robert, Gaztanaga, Juan, Weir, Matthew R., and Rajagopalan, Sanjay
- Subjects
- *
MINERALOCORTICOID receptors - Published
- 2024
- Full Text
- View/download PDF
40. SOTAGLIFLOZIN, A FIRST-IN-CLASS SGLT1/2 INHIBITOR, INHIBITS CLOTTING POTENTIAL IN THE VESSEL VIA INHIBITION OF PLATELET ACTIVATION, INTEGRIN ACTIVATION, AND AGGREGATION IN HUMAN PLATELETS.
- Author
-
Holinstat, Michael, Stanger, Livia, Rickenberg, Andrew, Yalavarthi, Pooja, Yamaguchi, Adriana, and Pitt, Bertram
- Subjects
- *
BLOOD platelet activation , *BLOOD platelet aggregation , *INTEGRINS , *THROMBIN receptors - Published
- 2024
- Full Text
- View/download PDF
41. SOTAGLIFLOZIN REDUCES STROKE OUTCOMES IN PATIENTS WITH DIABETES AND CHRONIC KIDNEY DISEASE.
- Author
-
Aggarwal, Rahul, Bhatt, Deepak L., Szarek, Michael, DAVIES, MICHAEL, Banks, Phillip, Pitt, Bertram, and Steg, Philippe Gabriel
- Subjects
- *
CHRONIC kidney failure , *STROKE patients , *PEOPLE with diabetes , *TREATMENT effectiveness - Published
- 2024
- Full Text
- View/download PDF
42. RELATIONSHIP BETWEEN INFLAMMATORY BIOMARKERS AND OUTCOMES: AN ANALYSIS FROM DEFINE-HF.
- Author
-
Sherrod, Charles, Sauer, Andrew, Patel, Shachi, Windsor, Sheryl, Nassif, Michael, Husain, Mansoor, Inzucchi, Silvio E., McGuire, Darren K., Pitt, Bertram, Scirica, Benjamin M., Austin, Bethany Anne, Umpierrez, Guillermo, Margulies, Kenneth B., Lanfear, David E., and Kosiborod, Mikhail
- Subjects
- *
BIOMARKERS - Published
- 2024
- Full Text
- View/download PDF
43. MODIFIED ON-TREATMENT ANALYSIS OF THE EFFECTS OF TORSEMIDE VS FUROSEMIDE AFTER DISCHARGE IN PATIENTS HOSPITALIZED WITH HEART FAILURE: RESULTS FROM TRANSFORM-HF.
- Author
-
Kittipibul, Veraprapas, Mentz, Robert John, Clare, Robert M., Wojdyla, Daniel, Anstrom, Kevin J., Eisenstein, Eric, Ambrosy, Andrew P., Goyal, Parag, Pitt, Bertram, Velazquez, Eric J., and Greene, Stephen
- Subjects
- *
HEART failure patients , *HOSPITAL admission & discharge , *FUROSEMIDE - Published
- 2024
- Full Text
- View/download PDF
44. EFFECTS OF SPIRONOLACTONE IN PATIENTS WITH HEART FAILURE ACROSS THE SPECTRUM OF KIDNEY RISK IN TOPCAT AMERICAS.
- Author
-
Chatur, Safia, Beldhuis, Iris, Neuen, Brendon, Claggett, Brian, Desai, Akshay S., Lewis, Eldrin F., Anand, Inderjit S., Shah, Sanjiv Jayendra, Sweitzer, Nancy K., Fang, James C., Pitt, Bertram, Pfeffer, Marc A., Vaduganathan, Muthiah, and Solomon, Scott D.
- Subjects
- *
HEART failure patients , *SPIRONOLACTONE , *KIDNEYS - Published
- 2024
- Full Text
- View/download PDF
45. Effectiveness of Digoxin in Reducing One-Year Mortality in Chronic Heart Failure in the Digitalis Investigation Group Trial
- Author
-
Ahmed, Ali, Waagstein, Finn, Pitt, Bertram, White, Michel, Zannad, Faiez, Young, James B., and Rahimtoola, Shahbudin H.
- Subjects
- *
DIGOXIN , *DRUG efficacy , *HEART failure , *HEART disease related mortality , *CHRONIC diseases , *HEART beat , *ACE inhibitors , *RANDOMIZED controlled trials - Abstract
Post hoc analyses of the Digitalis Investigation Group (DIG) trial indicate that digoxin at low (0.5 to 0.9 ng/ml) serum digoxin concentration (SDC) reduces mortality, which is eliminated at higher (≥1 ng/ml) SDC, and that low-dose digoxin (≤0.125 mg/day) predicts low SDC. In the DIG trial, patients with ambulatory chronic systolic and diastolic heart failure (HF) (n = 7,788) in normal sinus rhythm receiving angiotensin-converting enzyme inhibitors and diuretics were randomized to receive placebo (n = 3,899) or digoxin (n = 3,889). The median dose of digoxin (0.25 mg/day) and the target SDC (0.8 to 2.5 ng/ml) were higher than what are currently recommended, which in part may explain the lack of long-term mortality benefit of digoxin in the DIG trial. To test this hypothesis, we examined the effect of digoxin on short-term outcomes; 1-year all-cause mortality occurred in 392 and 448 patients respectively in the digoxin and placebo groups (hazard ratio for digoxin 0.87, 95% confidence interval [CI] 0.76 to 0.995, p = 0.043). Respective hazard ratios for cardiovascular and HF deaths were 0.87 (95% CI 0.76 to 1.01, p = 0.072) and 0.66 (95% CI 0.52 to 0.85, p = 0.001). All-cause hospitalization occurred in 1,411 and 1,529 patients receiving digoxin and placebo respectively (hazard ratio 0.89, 95% CI 0.83 to 0.96, p = 0.002). Respective hazard ratios for cardiovascular and HF hospitalizations were 0.82 (95% CI 0.75 to 0.89, p <0.0001) and 0.59 (95% CI 0.52 to 0.66, p <0.0001). In conclusion, digoxin reduced 1-year mortality and hospitalization in patients with chronic HF receiving angiotensin-converting enzyme inhibitors and diuretics. Randomized clinical trials are needed to determine the effect of low-dose digoxin in contemporary patients with chronic HF. [Copyright &y& Elsevier]
- Published
- 2009
- Full Text
- View/download PDF
46. Role of Aldosterone Blockade for Treatment of Heart Failure and Post–Acute Myocardial Infarction
- Author
-
Greenberg, Barry, Zannad, Faiez, and Pitt, Bertram
- Subjects
- *
MYOCARDIAL infarction , *CORONARY disease , *HEART diseases , *THERAPEUTICS , *HEART failure - Abstract
Heart failure continues to significantly impact morbidity and mortality after acute myocardial infarction (AMI), especially when associated with left ventricular systolic dysfunction (LVSD). Therefore, routine use of optimal therapy for patients with heart failure after AMI is needed in the future. Data from the Eplerenone Post–Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS) has demonstrated that addition of eplerenone to standard therapy in patients with LVSD and clinical heart failure post-AMI significantly improves outcomes in these patients, providing the basis for acceptance of aldosterone blockade as an integral component of therapy. However, further studies are needed to more broadly explore the usefulness of aldosterone blockade in heart failure therapy. As research clarifies the many complex pathophysiologic processes involved in post-AMI remodeling, treatment should continue to move beyond symptom-targeted therapies to disease- and mechanism-targeted therapies that will further improve outcomes in the setting of heart failure post-AMI and beyond. [Copyright &y& Elsevier]
- Published
- 2006
- Full Text
- View/download PDF
47. Diuretic use, progressive heart failure, and death in patients in the studies of left ventricular dysfunction (SOLVD)
- Author
-
Domanski, Michael, Norman, James, Pitt, Bertram, Haigney, Mark, Hanlon, Stephen, Peyster, Eliot, and Studies of Left Ventricular Dysfunction
- Subjects
- *
DIURETICS , *HEART failure , *ANGIOTENSINS - Abstract
: ObjectivesWe sought to determine whether non–potassium-sparing diuretics (PSDs) in the absence of a PSD may result in progressive heart failure (HF).: BackgroundAngiotensin-converting enzyme (ACE) inhibitors incompletely suppress ACE activity in HF patients. Furthermore, non-PSDs are activators of aldosterone secretion. We reasoned that non-PSDs, in the absence of a PSD, might result in progressive HF.: MethodsIn the 6,797 patients in the Studies Of Left Ventricular Dysfunction (SOLVD), we compared the risk of hospitalization for, or death from, HF between those taking a PSD and those who were not, adjusting for known covariates.: ResultsThe risk of hospitalization from worsening HF in those taking a PSD relative to those taking only a non-PSD was 0.74 (95% confidence interval [CI] 0.55 to 0.99; p = 0.047). The relative risk for cardiovascular death was 0.74 (95% CI 0.59 to 0.93; p = 0.011), for death from all causes 0.73 (95% CI 0.59 to 0.90; p = 0.004), and for hospitalization for, or death from, HF 0.75 (95% CI 0.58 to 0.97; p = 0.030). Compared with patients not taking any diuretic, the risk of hospitalization or death due to worsening HF in patients taking non-PSDs alone was significantly increased (risk ratio [RR] = 1.31, 95% CI 1.09 to 1.57; p = 0.0004); this was not observed in patients taking PSDs with or without a non-PSD (RR = 0.99, 95% CI 0.76 to 1.30; p = 0.95).: ConclusionsThe use of PSDs in HF patients is associated with a reduced risk of death from, or hospitalization for, progressive HF or all-cause or cardiovascular death, compared with patients taking only a non-PSD. [Copyright &y& Elsevier]
- Published
- 2003
- Full Text
- View/download PDF
48. Time to retrieve the best benefits from renin angiotensin aldosterone system (RAAS) inhibition in heart failure patients with reduced ejection fraction: Lessons from randomized controlled trials and registries.
- Author
-
Rossignol, Patrick, Zannad, Faiez, and Pitt, Bertram
- Subjects
- *
RENIN-angiotensin system , *HEART failure patients , *HEART failure treatment , *RANDOMIZED controlled trials , *MINERALOCORTICOID receptors , *HOSPITAL care - Abstract
Numerous registries, including the most recent ESC Euro-observational registry, have reported a large and persistent gap between real-life practice in the use of life-saving evidence-based therapies (such as renin angiotensin antagonists, beta-blockers, mineralocorticoid receptor antagonists) and recommended practices in international guidelines. Although the use of multiple renin angiotensin aldosterone system-inhibitors is associated with the development of worsening renal function and hyperkalemia in patients with heart failure and reduced ejection fraction, increased efforts should be expended to initiate and maintain target doses of these agents so as to provide their benefits on mortality and hospitalizations for heart failure. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
49. Spironolactone in Patients With Heart Failure, Preserved Ejection Fraction, and Worsening Renal Function.
- Author
-
Beldhuis, Iris E., Myhre, Peder L., Bristow, Michael, Claggett, Brian, Damman, Kevin, Fang, James C., Fleg, Jerome L., McKinlay, Sonja, Lewis, Eldrin F., O'Meara, Eileen, Pitt, Bertram, Shah, Sanjiv J., Vardeny, Orly, Voors, Adriaan A., Pfeffer, Marc A., Solomon, Scott D., and Desai, Akshay S.
- Subjects
- *
HEART failure patients , *KIDNEY physiology , *SPIRONOLACTONE , *PROPORTIONAL hazards models , *TREATMENT effectiveness , *HEART failure , *GLOMERULAR filtration rate , *RESEARCH , *KIDNEYS , *RESEARCH methodology , *MEDICAL cooperation , *EVALUATION research , *KIDNEY diseases , *COMPARATIVE studies , *ALDOSTERONE antagonists , *BLIND experiment , *RESEARCH funding , *STROKE volume (Cardiac output) , *LONGITUDINAL method , *PHARMACODYNAMICS - Abstract
Background: Treatment of heart failure with preserved ejection fraction (HFpEF) with spironolactone is associated with lower risk of heart failure hospitalization (HFH) but increased risk of worsening renal function (WRF). The prognostic implications of spironolactone-associated WRF in HFpEF patients are not well understood.Objectives: The purpose of this study was to investigate the association between WRF, spironolactone treatment, and clinical outcomes in patients with HFpEF.Methods: In 1,767 patients randomized to spironolactone or placebo in the TOPCAT (Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist Trial)-Americas study, we examined the incidence of WRF (doubling of serum creatinine) by treatment assignment. Associations between incident WRF and subsequent risk for the primary study endpoint of cardiovascular (CV) death, HFH, or aborted cardiac arrest and key secondary outcomes, including CV death, HFH, and all-cause mortality according to treatment assignment, were examined in time-updated Cox proportional hazards models with an interaction term.Results: WRF developed in 260 (14.7%) patients with higher rates in those assigned to spironolactone compared to placebo (17.8% vs. 11.6%; odds ratio: 1.66; 95% confidence interval: 1.27 to 2.17; p < 0.001). Regardless of treatment, incident WRF was associated with increased risk for the primary endpoint (hazard ratio: 2.04; 95% confidence interval: 1.52 to 2.72; p < 0.001) after multivariable adjustment. Although there was no statistical interaction between treatment assignment and WRF regarding the primary endpoint (interaction p = 0.11), spironolactone-associated WRF was associated with lower risk of CV death (interaction p = 0.003) and all-cause mortality (interaction p = 0.001) compared with placebo-associated WRF.Conclusions: Among HFpEF patients enrolled in TOPCAT-Americas, spironolactone increased risk of WRF compared with placebo. Rates of CV death were lower with spironolactone in both patients with and without WRF. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
50. Abnormalities of Potassium in Heart Failure: JACC State-of-the-Art Review.
- Author
-
Ferreira, João Pedro, Butler, Javed, Rossignol, Patrick, Pitt, Bertram, Anker, Stefan D, Kosiborod, Mikhail, Lund, Lars H, Bakris, George L, Weir, Matthew R, and Zannad, Faiez
- Subjects
- *
GASTROINTESTINAL disease diagnosis , *GASTROINTESTINAL diseases , *HEART failure , *HYPOKALEMIA , *POTASSIUM , *HYPERKALEMIA - Abstract
Potassium (K+) is the most abundant cation in humans and is essential for normal cellular function. Alterations in K+ regulation can lead to neuromuscular, gastrointestinal, and cardiac abnormalities. Dyskalemia (i.e., hypokalemia and hyperkalemia) in heart failure is common because of heart failure itself, related comorbidities, and medications. Dyskalemia has important prognostic implications. Hypokalemia is associated with excess morbidity and mortality in heart failure. The lower the K+ levels, the higher the risk, starting at K+ levels below approximately 4.0 mmol/l, with a steep risk increment with K+ levels <3.5 mmol/l. Hyperkalemia (>5.5 mmol/l) has also been associated with increased risk of adverse events; however, this association is prone to reverse-causation bias as stopping renin angiotensin aldosterone system inhibitor therapy in the advent of hyperkalemia likely contributes the observed risk. In this state-of-the-art review, practical and easy-to-implement strategies to deal with both hypokalemia and hyperkalemia are provided as well as guidance for the use of potassium-binders. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.